Table III.
Difference in HAQ-DI, QALY, and improvement of DAS28 and direct costs according to treatment regimen per patient
| Infliximab | Etanercept | Adalimumab | |
|---|---|---|---|
| Decrease of HAQ-DI | 0.45 | 0.21 | 0.18 |
| QALY | 1.71 | 0.74 | 0.60 |
| Improvement of DAS28 | 3.30 | 3.51 | 3.70 |
| Average medical cost per patient | 64,263.61 | 72,866.19 | 81,494.04 |
DAS28 – Disease Activity Score 28; HAQ-DI – Health Assessment Questionnaire Disability Index; QALY – quality-adjusted life years